16 May
2022
08:30 E.S.T.

Cellectis Presents Research Data on a Novel Immune-Evasive Universal CAR T-cell at ASGCT

Read more

12 May
2022
16:30 E.S.T.

Cellectis Provides Business Update and Reports Financial Results for First Quarter 2022

Read more

05 May
2022
16:30 E.S.T.

Cellectis to Report First Quarter 2022 Financial Results

Read more

05 May
2022
16:00 E.S.T.

Calyxt, Inc., Cellectis’ Majority-Owned Subsidiary, Reports Its First Quarter 2022 Financial Results

Read more

28 Apr
2022
08:00 E.S.T.

Cellectis Publishes Two Articles in Nature Communications Providing Strong Preclinical Validation of UCART123 to Treat AML and BPDCN

Read more

27 Apr
2022
04:00 E.S.T.

Cellectis Receives $20 Million Convertible Note Under Collaboration Agreement with its Partner Cytovia Therapeutics

Read more

08 Apr
2022
16:30 E.S.T.

Cellectis Presents Preclinical Data from its First Allogeneic Dual CAR T-cell Product Candidate UCART20x22 for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma at the American Association for Cancer Research (AACR) 2022 Annual Meeting

Read more

11 Mar
2022
13:15 E.S.T.

Cellectis to Participate in Two Upcoming Investor Conferences in March

Read more

03 Mar
2022
13:46 E.S.T.

Cellectis Provides Business Update and Reports 4th Quarter and Full Year 2021 Financial Results

Read more

24 Feb
2022
13:13 E.S.T.

Cellectis to Hold Fourth Quarter 2021 Earnings Call on Friday March 4, 2022 at 8:00AM EST

Read more